Active Ingredient(s): Ivacaftor + Tezacaftor
FDA Approved: * February 12, 2018
Pharm Company: * VERTEX PHARMS INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Symdeko Overview

Tezacaftor is a drug used for the treatment of cystic fibrosis (CF) in people six years and older, who have specific gene mutations.[1][2] It is normally sold as a fixed-dose combination with ivacaftor.[3][4][5] In 2018, the U.S. Food and Drug Administration (FDA) approved a combination of ivacaftor and tezacaftor;[1] the manufacturer announced a list price of $292,000 per year.[6]...

Read more Symdeko Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Symdeko Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ivacaftor + Tezacaftor
  • Tablet: 150mg + 150mg, 100mg, 75mg + 75mg, 50mg
  • Tablet, Tablet: 150mg,n/a + 150mg, 100mg, 75mg,n/a + 75mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Symdeko: (2 results)

Sorted by National Drug Code
  • 51167-113 SymdekoSymdeko Kit by Vertex Pharmaceuticals Incorporated
  • 51167-661 Symdeko Kit by Vertex Pharmaceuticals Incorporated

Drugs with one or more similar ingredients: (7 results)